Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.30 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.30 |
| ▸ | ATP2A2 | P16615 | 1/20 | 0.30 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
| ▸ | ATP2A3 | Q93084 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18007542 | 0.71 | CA2 (0.40) | L3MBTL1KDM4EALDH1A1 | |
| SCHEMBL22012006 | 0.67 | — | — | |
| SCHEMBL21720688 | 0.66 | ALDH1A1 (0.34) | L3MBTL1KDM4EALDH1A1CYP1A2MAPT | |
| SCHEMBL22012005 | 0.66 | LIPG (0.30) | — | |
| SCHEMBL10165404 | 0.65 | ALDH1A1 (0.37) | L3MBTL1KDM4EALDH1A1CYP1A2MAPT | |
| SCHEMBL20680951 | 0.64 | — | — | |
| SCHEMBL820796 | 0.63 | L3MBTL1 (0.48) | L3MBTL1KDM4EALDH1A1CYP1A2MAPT | |
| SCHEMBL31748021 | 0.63 | TDP1 (0.42) | L3MBTL1KDM4EALDH1A1MAPT | |
| SCHEMBL20680922 | 0.63 | — | — | |
| SCHEMBL15307453 | 0.62 | ALDH1A1 (0.34) | L3MBTL1KDM4EALDH1A1CYP1A2MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2020102576-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH NLRP ACTIVITY | NOVARTIS INFLAMMASOME RESEARCH, INC. (US) | 2020-05-22 | — | — | WO | disclosed |